<DOC>
	<DOCNO>NCT02658890</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness experimental medication BMS-986205 , combine Nivolumab patient cancer advance spread .</brief_summary>
	<brief_title>An Investigational Immuno-therapy Study BMS-986205 Given Combination With Nivolumab Cancers That Are Advanced Have Spread .</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BristolMyers Squibb ( BMS ) Clinical Trial participation , please visit www.BMSStudyConnect.com Patients must diagnose cancer least 1 prior standard treatment Must able swallow pill capsule Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 Any prior ongoing clinical study Nivolumab overall survival endpoint Requirement daily supplemental oxygen Myocardial infarction stroke/transient ischemic attack within past 6 month Uncontrolled angina within past 3 month History chronic Hepatitis , active Hepatitis B C , human immunodeficiency virus ( HIV ) , acquire immune deficiency syndrome ( AIDS ) Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>